Literature DB >> 3460170

Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa.

E Carlsson, H Larsson, H Mattsson, B Ryberg, G Sundell.   

Abstract

Omeprazole is a long acting inhibitor of gastric acid secretion in different species including rat and dog. Due to the long duration of action, steady state inhibition at repeated once daily administration is reaches within 4-5 days in dogs and in about 3 days in rats. Daily dosing at high dose levels results in virtually complete 24-hour inhibition of acid secretion in experimental animals. The elimination of the inhibitory feedback effect of acid on gastrin secretion leads to hypergastrinaemia. Because gastrin has a trophic effect on the oxyntic mucosa, the hypergastrinaemia results in a reversible hypertrophy of the oxyntic mucosa and an increased capacity to produce acid following maximal stimulation with exogenous secretagogues after discontinuing treatment. Despite the increased capacity to produce acid, basal acid secretion seems to be unchanged. The pronounced hypergastrinaemia which occurs during long-term treatment with high doses rapidly normalizes after discontinuing treatment. The hyperplasia of the oxyntic endocrine ECL cells, and the eventual development of gastric ECL cell carcinoids after lifelong treatment of rats with high doses, can also be attributed to the hypergastrinaemia developing after almost complete elimination of gastric acid secretion in these animals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3460170     DOI: 10.3109/00365528609090884

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  19 in total

1.  Antisecretory therapy and genotoxicity.

Authors:  S Holt; R E Powers; C W Howden
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

2.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

3.  Effects of esomeprazole magnesium on nonsteroidal anti-inflammatory drug gastropathy.

Authors:  Timothy R Koch; Ann Petro; Marcus Darrabie; Emmanuel C Opara
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

4.  Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.

Authors:  Malcolm Boyce; Frans van den Berg; Toni Mitchell; Kate Darwin; Steve Warrington
Journal:  Eur J Clin Pharmacol       Date:  2016-10-29       Impact factor: 2.953

Review 5.  Optimal reduction of gastric acid secretion in the treatment of peptic ulceration.

Authors:  H G Dammann; M Dreyer; R Kangah; P Müller; B Simon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.

Authors:  D K Driman; C Wright; G Tougas; R H Riddell
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 7.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 8.  Safety profile of Lansoprazole: the US clinical trial experience.

Authors:  J W Freston; P A Rose; C A Heller; M Haber; D Jennings
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

Review 9.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

10.  Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man.

Authors:  J L Meijer; J B Jansen; L F Crobach; I Biemond; C B Lamers
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.